

OFFICE
DEC 14 2001
TRADE MARK OFFICE

MAIL DATE 2000
JCT 12
CANCELLED

EXPRESS MAIL NO.: EL 477832 796 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
DEC 19 2001
TECH CENTER 1600/2800

Application of: Santoro et al.

Application No.: 09/533,399

Group Art Unit: 1617

Filed: March 22, 2000

Examiner: Travers, R.

For: METHODS OF TREATING
INFLAMMATORY AND VIRAL
DISORDERS BY ADMINISTERING
CYCLOPENTENONE COMPOUNDS

Attorney Docket No.: 10167-004

**PRELIMINARY AMENDMENT AND
RESPONSE TO RESTRICTION REQUIREMENT**

*s/a
A. Harmon
1/15/02*

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Restriction Requirement, mailed June 27, 2001, and in accordance with Rules 115 and 143 of the Rules of Practice, please enter the following amendments and consider the remarks below. Applicants submit herewith: (1) Exhibit A, a marked up version of the paragraphs in the specification amended herein; (2) Exhibit B, a marked up version of the claim amended herein; (3) Exhibit C, a copy of the pending claims; (4) a Petition For Extension Of Time (in duplicate) to extend the period of response from July 27, 2001 to December 27, 2001, accompanied by a provision authorizing payment of the required fee; (5) an Amendment Fee Transmittal, accompanied by a provision authorizing payment of the required fee; and (6) a Supplemental Information Disclosure Statement.

IN THE SPECIFICATION:

On page 2, please replace the paragraph beginning on line 1 with the following paragraph:

One successful approach in combating viral infections appears to be the simultaneous use of two or more drugs that affect different targets during the virus life cycle. A group of prostaglandins (PG) and PG-derivatives containing an α,β -unsaturated carbonyl group in the

a